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Abstract
Undernutrition is common among smear-positive pulmonary tuberculosis (PTB þ ) patients. Micronutrient supplementation may improve
treatment outcomes, but it is unclear whether additional energy–protein would be beneficial. The present study aimed to assess the effect
of energy–protein supplementation on weight, body composition and handgrip strength against a background of high micronutrient
intake during tuberculosis (TB) treatment. A total of 377 PTB þ patients co-infected with HIV were randomly allocated one or six biscuits
daily for 60 d during TB treatment. Weight, arm fat area, arm muscle area and handgrip strength were assessed at baseline and 2 and
5 months. There were no effects on any outcome at 2 months, but energy–protein supplementation was associated with a 1·3 (95 % CI
20·1, 2·8) kg marginally significant gain in handgrip strength at 5 months. However, after 2 months, energy–protein supplementation
led to a weight gain of 1·9 (95 % CI 0·1, 3·7) kg among patients with cluster of differentiation 4 (CD4) counts $350 cells/ml, but
not among patients with low CD4 counts (20·2 kg; 95 % CI 21·3, 0·8, Pinteraction ¼ 0·03). Similarly, at 5 months, energy–protein
supplementation led to a 2·3 (95 % CI 0·6, 4·1) kg higher handgrip strength gain among patients with CD4 counts ,350 cells/ml, but
not in those with high CD4 counts (Pinteraction ¼ 0·04). In conclusion, energy–protein supplementation to PTB þ HIV-co-infected patients
had no overall effects on weight and body composition, but was associated with marginally significant gain in handgrip strength. More
research is needed to develop an effective supplement, before it is recommended to TB programmes.
Key words: Energy–protein supplementation: Pulmonary tuberculosis: HIV: Clinical trials
Tuberculosis (TB) remains a major global health problem, with
9·4 million new cases and 1·7 million deaths each year(1). HIV
infection increases the risk of reactivation of latent TB(2) and in
settings where HIV prevalence is high; HIV co-infection may
be above 50 % in TB patients(3,4).
Both TB and HIV cause undernutrition due to reduced food
intake and increased utilisation of energy and nutrients(5–7) and
the co-existence of the two diseases may lead to more under-
nutrition(8–10). Despite advances in HIV and TB management,
undernutrition is common among HIV-infected TB patients(11)
and may affect treatment outcome and survival(12) and regain
of functional abilities. Thus, nutritional support should be an inte-
grated component of casemanagement, although there are insuf-
ficient data on the optimal nutrient amounts and composition(13).
*Corresponding author: Dr G. PrayGod, fax þ255 28 2500654, email gpraygod@yahoo.com
Abbreviations: ART, antiretroviral therapy; CD4, cluster of differentiation 4; NTLP, National TB and Leprosy Programme; PTB, pulmonary tuberculosis; TB,
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In a recent two-by-two factorial trial among sputum-positive
pulmonary tuberculosis (PTB þ ) patients in Tanzania, we
found that daily supplementation with Zn and other micronu-
trients increased weight gain by 2·4 kg and reduced mortality
by 70 % among those co-infected with HIV(12). Based on
these findings, we conducted two trials to further examine
the effects of nutritional support on weight, body composition
and handgrip strength. Among PTBþ/HIVþ patients,
we assessed the effects of adding energy–protein to the
multi-micronutrient supplement previously found to improve
survival(12), whereas among PTBþ/HIV2, PTB2/HIVþ and
PTB2/HIV2 patients, the effects of multi-micronutrient sup-
plementation were assessed(14). Here, we report the results
of the first trial.
Subjects and methods
Study setting and recruitment
The study was conducted from April 2006 to March 2009 at
four TB clinics in Mwanza city, under the Tanzanian National
TB and Leprosy Programme (NTLP). Although the incidence
of TB is still high in Tanzania (183 per 100 000 population
in 2009), the cure rate is 84 %(1), and the prevalence of
multi-drug resistance TB is only 1·1 % among new cases and
3·9 % among relapse cases(15).
New or relapse(16) PTB þ HIV-co-infected patients were
enrolled in the study after giving a written informed consent
if they were residents of Mwanza city. Patients with extra-
pulmonary TB, pregnancy, age under 15 years or terminal
illness were excluded. Patients who were either PTB 2 or
HIV 2 were included in a concurrent trial(14).
The diagnosis and treatment of TB followed established
guidelines(17). Briefly, all TB suspects were asked to bring
three sputum samples for sputum microscopy and were
asked to do a chest X-ray as appropriate(17,18). Patients were
classified as PTB þ , if two samples tested positive or one
sample tested positive and a chest X-ray was suggestive of
TB. After diagnosis, all patients were started on TB treatment
based on existing national guidelines(16). However, the treat-
ment duration and mode of supervision for patients diagnosed
with TB for the first time changed 6 months after the study
started(19). From April 2006 to the end of September 2006,
the total TB treatment period was 8 months using single
drug tablets. Rifampicin, isoniazid, pyrazinamide and etham-
butol were used in the first 2 months (intensive phase) and
ethambutol and isoniazid for the last 6 months (continuation
phase). Patients were observed daily for the intake of drugs
at the health facility by a health worker during the intensive
phase. During the continuation phase, patients collected
drugs from the health facility on a monthly basis for self-
administration at their homes. From 1 October 2006, the
NTLP reduced treatment duration from 8 to 6 months and
introduced new drug formulations and mode of supervision.
During this period, the same regimen consisting of rifampicin,
isoniazid, pyrazinamide and ethambutol in a multi-drug tablet
was used during the intensive phase and rifampicin and iso-
niazid were used during the continuation phase (4 months).
Patients were asked to choose either to have their treatment
supervised at home or at the health facility. Those who
chose home-based supervision had to select a person to
supervise their daily treatment at home. Also, they had to
collect drugs from the health facility once weekly during the
intensive phase and every 2 weeks during the continuation
phase. Those who chose health facility-based supervision
had to take the drugs daily at the clinic throughout the treat-
ment period. In both time periods, patients who were being
re-treated for TB, received treatment for 8 months and their
drug intake was observed daily at the health facility(17).
The management of HIV infection was done based on
national guidelines at the time of the study(20). Patients were
immediately initiated on antiretroviral therapy (ART) if they
had a cluster of differentiation 4 (CD4) count of ,200 cells/ml,
those with a WHO stage 4 illness and/or a CD4 count of
200–350 cells/ml were initiated on ART after completion of
2 months of TB treatment, and the need for ART was assessed
after completion of TB treatment for patients with a CD4
count of .350 cells/ml. Patients who developed TB after
starting ART were allowed to continue with ART throughout
TB treatment.
Study design and interventions
The study was a randomised controlled trial assessing
the effect of energy–protein supplementation among HIV-
infected PTB þ patients on weight, arm fat area, arm
muscle area and handgrip strength. Patients were randomised
to receive one or six energy–protein biscuit bars daily for 60 d
during the first 2 months of TB treatment. One of the biscuit
bars given to the experimental group and the one given
to the control group contained additional micronutrients, so
that the supplemental micronutrient intake was similar in the
two groups. Each energy–protein biscuit bar weighed 30 g
and contained 4·5 g protein, 615 kJ energy, and 120 mg P,
120 mg Ca, 36 mg Mg, 70 mg Na, 150 mg K and only traces
(,1 mg) of Fe and Zn. The biscuit bar with additional micro-
nutrients also contained the following: vitamin A 1·5 mg,
vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin
B12 50mg, folic acid 0·8 mg, niacin 40 mg, vitamin C 200 mg,
vitamin E 60 mg, vitamin D3 5mg, Se 0·2 mg, Cu 5 mg and Zn
30 mg. The amount of additional micronutrients was similar to
what was found beneficial among TB patients previously(12).
The products were manufactured by Compact AS (Bergen,
Norway) for the present trial, based on modification of a
commercial product as requested by the researchers. Thus,
each day, patients in the intervention arm received a total of
3690 kJ and 27 g protein, whereas those in the control arm
received 615 kJ and 4·5 g protein. As a result, the trial
tested the effect of providing about 50 % of the daily energy
requirement, and of the RDA for protein(21) based on an
average of 60 kg weight for non-TB controls in this setting(22).
The levels of micronutrients in the two arms were similar,
although the levels for P, Ca and Mg were slightly higher in
the intervention arm.
In order to match the mode of TB drug intake and supervi-
sion, in the first 6 months of the study, all supplements were
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taken under the observation of clinic staff, whereas from 1
October 2006 to the end of the study, most patients (90 %)
took their supplements at home under the supervision of a
home-based supporter, since they had also chosen to take
their TB drugs at home. In this period, patients were advised
against sharing the supplements with any family member and
were asked to come to the TB clinic to collect their sup-
plements every 6–12 d. The remaining 10 % of patients contin-
ued with health facility-based supplement intake supervision.
Randomisation and allocation concealment
Patients were allocated to treatment arms following a compu-
ter-generated randomisation sequence, using permuted blocks
of ten. The sequence was generated using the website http://
www.randomization.com, and used by a designated research
staff to sequentially arrange and label supplement packs with
identity numbers ranging from 1 to 500. During the study, the
randomisation sequence and code were kept in a safe cabinet
and was only accessible to the designated research staff.
Recruitment was done by TB clinic staff. Then, the same desig-
nated research staff who was not employed at any of the
TB clinics assigned an identity number to the recruited patient,
and sent the corresponding nutritional supplement pack
to the respective clinic. Thereafter, TB clinic staff were
responsible for dispensing the supplements and keeping the
intake records. The present trial was not blinded since both
patients and TB clinic staff could discern the experimental
intervention.
Outcome measures
The primary outcomes were weight gain at 2 and 5 months,
i.e. at the end of the supplementation period and 3 months
after. Secondary outcomes were gains in arm fat area, arm
muscle area and handgrip strength at 2 and 5 months.
Data collection
Data on demography, smoking and alcohol intake were col-
lected using questionnaires while data on ART were retrieved
from antiretroviral use databases in ART clinics. Between 08.00
and 12.00 hours, blood was collected in a 10 ml plain vacutai-
ner tube for HIV testing and a 5 ml EDTA vacutainer tube
for CD4 count. HIV status was determined using Capillus
HIV-1/HIV-2 (Trinity Biotech Plc., Wicklow, Ireland) and
Determine HIV-1/HIV-2 (Inverness Medical Innovations, Inc.,
Newark, DE, USA) tests in parallel. HIV infection was diag-
nosed if both tests gave a positive result and HIV-negative
diagnosis was made if both tests produced a negative result.
Indeterminate results were resolved using ELISA-Organon
Uniform II (Organon Teknia Limited, Boxtel, The Nether-
lands). CD4 count was determined as cells/ml using a Partec
Cyflow Counter (Partec GmbH, Mu¨nster, German).
Weight was determined to the nearest 0·1 kg using a digital
scale (Seca, Australia) and height was determined to the near-
est 0·1 cm using a height board. Mid-upper arm circumference
was determined to the nearest 0·1 cm using a tape measure,
and triceps skinfold thickness was determined to the nearest
0·1 mm using the Harpenden caliper on the left arm. Measure-
ments were made in duplicate, and are reported as mean
values. Based on mid-upper arm circumference and triceps
skinfold thickness measurements, arm muscle area and
arm fat area were calculated as described previously(23) and
BMI was calculated as weight (kg)/(height (m))2. Handgrip
strength was determined to the nearest 0·1 kg using a digital
dynamometer (Takei Scientific Instruments Company Limited,
Tokyo, Japan). A total of four measurements were taken, with
the mean of the two maximum measurements (one in each
hand) reported. All measurements were done at recruitment
and repeated at the end of 2 and 5 months. Training was
provided before the study, and regular supervision was done
to ensure adherence of the protocol and the same staff did the
measurements throughout the study.
Ascertainment of supplement intake
Before October 2006, TB clinic staff recorded directly the
intake of supplements after patients had taken the supplement
under their supervision. From October 2006 onwards, patients
who chose to take supplements at home were asked to record
the intake of supplements using a log designed for this
purpose. When patients came to collect another pack of
nutritional supplements, the log was handed to the TB clinic
for updating the supplement intake record. Intake of at
least 80 % of the supplements was regarded as adequate
compliance.
Sample size and power considerations
We planned to recruit 500 PTB patients. In a previous
trial, we found that the standard deviation for weight gain
in the first 2 months was 3·5 kg (N Range, AB Andersen,
A Mugomela and H Fru¨s). Therefore, we would be able to
detect a 0·95 kg or a greater weight-gain difference with
80 % power and 5 % significance level, while allowing for
15 % loss to follow-up. With recruitment of 377 patients and
a 12 % loss to follow-up, we would be able to detect an overall
1·1 kg weight-gain difference between the two groups.
Statistical analysis
Data were twice entered in EpiData (EpiData Association,
Odense, Denmark) and analysed using Stata/IC version 10
(StataCorp LP, College Station, TX, USA). Normal probability
plots were used to assess normality of the continuous
variables. Differences in categorical and continuous variables
between groups were tested using the x 2 test and t test,
respectively. Additionally, linear regression was used to
adjust for potential confounders and to test for interactions
with respect to baseline CD4 count groups (,350 or
$350 cells/ml), sex, ART during supplementation and mode
of supplementation (clinic- v. home-based supplementation).
Where interaction was detected, the effect of the intervention
was assessed by the level of the effect modifier. Analysis was
done on an intention-to-treat basis. P values below 0·05 were
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considered significant. The trial was registered at Clinical-
Trials.gov (http://clinicaltrials.gov) identifier: NCT00311298.
Ethical considerations
The present study was conducted according to the guidelines
laid down in the Declaration of Helsinki. Written informed
consent was obtained from all patients enrolled in the present
study. Ethical permission was obtained from the National
Medical Research Coordinating Committee of the National
Institute of Medical Research in Tanzania and approval from
the Danish National Committee on Biomedical Research
Ethics. Patients who did not know their HIV status were
offered pre- and post-test HIV counselling and referred to
nearby ART clinics for management.
Results
Of the 1042 TB patients who were screened at TB clinics
during the recruitment period, 398 (38·2 %) were eligible,
of which 377 (94·7 %) consented to participate in the trial.
As seen in the trial profile (Fig. 1), of those not eligible,
154 (23·9 %) had extra-pulmonary TB, 376 (58·4 %) were
non-residents and the remaining 114 (17·7 %) were aged
,15 years, terminally ill or pregnant. Of the 377 recruited,
the mean age was 35·4 (range 16–80) years, BMI was 18·6
(SD 2·9) kg/m2, and 187 (49·6 %) were females and 261
(69·4 %) had CD4 cell counts below 350 cells/ml. Baseline
CD4 count data for one patient in the energy–protein group
were not available.
Randomisation achieved baseline equivalence of back-
ground characteristics (Table 1). At 2 and 5 months, forty-six
(12·2 %) and seventy-two (19·1 %) patients were lost to
follow-up, respectively. However, at both time points, the pro-
portions lost to follow-up were similar across intervention and
control arms (13·2 v. 11·2 %; P¼0·54 and 19·6 v. 18·6 %;
P¼0·81, respectively). At 2 months, those lost to follow-up
had lower arm muscle area (29·6 v. 33·8 cm2; P¼0·03),
whereas those lost at 5 months had lower weight (48·5 v.
51·5 kg; P¼0·01) and arm muscle area (30·4 v. 34·0 cm2;
P¼,0·001). The proportion of patients on ART kept on
increasing after study entry, but this proportion did not
differ between intervention and control arms at 2 and 5
months (25·9 v. 21·3 %; P¼0·29 and 33·3 v. 32·5 %; P¼0·86,
respectively). In addition, throughout the follow-up period,
the group with CD4 counts ,350 cells/ml had a larger pro-
portion of patients on ART (Table 2).
Overall, study patients had considerable weight and hand-
grip strength gain by the end of 2 and 5 months of treatment.
However, energy–protein supplementation had no main
effects on gain in weight, arm fat and muscle area, and hand-
grip strength at 2 and 5 months, but was associated with a
marginally significantly higher increase in handgrip strength
(1·3 kg; 95 % CI 20·1, 2·8; P¼0·07) at 5 months (Table 3).
At 2 months, there was an interaction between energy–
protein supplementation and CD4 count level for weight
(Pinteraction ¼ 0·03), which was explained by a 1·9 kg (95 % CI
0·1, 3·7; P¼0·04) higher weight gain among patients with
CD4 counts of 350 cells/ml or higher, and the lack of effect
among those who had CD4 counts below 350 cells/ml
(20·2 kg; 95 % CI 21·3, 0·8; P¼0·66). The beneficial effect
Assessed for eligibility (n 1042)
Randomised (n 377)
Ineligible (n 644)
  Extra-pulmonary TB (n 154)
  Non-residents (n 376)
  Age <15 years (n 61)
  Terminally ill (n 38)
  Pregnant (n 15)
Eligible, but refused (n 21)
Energy–protein arm (n 189) Control arm (n 188)
Followed-up at 2 months (n 164)
Followed-up at 5 months (n 152)
Followed-up at 2 months (n 167)
Followed-up at 5 months (n 153)
Lost (n 25) Lost (n 21)
Lost (n 12) Lost (n 14)
Fig. 1. Trial flow chart. TB, tuberculosis.
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seemed to be accompanied by changes in both arm fat and
muscle area, though the estimates were not significant
(Table 4). After 5 months, there was an interaction between
energy–protein supplementation and CD4 count level for
handgrip strength (Pinteraction ¼ 0·04), which was explained
by a 2·3 kg (95 % CI 0·6, 4·1; P¼0·009) higher gain in handgrip
strength among those with CD4 counts of ,350 cells/ml
and lack of effect among those with higher CD4 counts
(21·0 kg; 95 % CI 23·5, 1·5; P¼0·43; Table 4). Interestingly,
at 5 months, there was a marginally significant interaction
between energy–protein supplementation and ART use for
handgrip strength (Pinteraction ¼ 0·08) due to a greater effect
of energy–protein supplementation on handgrip strength
among those on ART (3·0 kg; 95 % CI 0·5, 5·6; P¼0·02)
but not among those not on ART (0·4 kg; 95 % CI 21·3,
1·5; P¼0·61).
Proportions of patients with adequate compliance did not
differ between the period when supplements were taken in
clinics compared with when they were taken mainly at
home (90·6 v. 87·4 %; P¼0·47). Similarly, in both periods,
the proportions of patients with adequate compliance did
not differ between the study arms (P¼0·34 and P¼0·66,
respectively). Furthermore, the effect of the intervention
on weight at 2 months was not modified by compliance
(Pinteraction ¼ 0·52). There was no confounding or effect modi-
fication by sex and mode of supplementation.
Discussion
The present study was based on the results of our earlier two-
by-two factorial trial in which PTB þ patients were random-
ised to either multi-micronutrients (excluding Zn) or placebo,
and independently to Zn or placebo, to be taken daily along-
side TB treatment for 8 months(12). In this earlier trial, we
found that by the end of the 7th month of supplementation,
there was an interaction between Zn and other micronutrients,
Table 1. Baseline characteristics of 377 pulmonary tuberculosis patients randomised to either the energy–protein or control group
(Percentages, number of patients, mean values and standard deviations)
Energy–protein group (n 189) Control group (n 188)
Prevalence (%) n Mean SD Prevalence (%) n Mean SD
Age (years) 34·7 10·3 36·2 9·5
Female sex 50 94 49 93
BMI (kg/m2) 18·7 2·9 18·5 2·8
BMI (kg/m2) groups
, 16 14·9 28 13·3 25
16–16·9 14·4 27 15·4 29
17–18·49 22·3 42 27·7 52
$ 18·5 48·4 91 43·6 82
Ethnicity
Wasukuma 52 98 52 97
Others 48 91 48 91
Marital status
Single 25 47 22 41
Married/co-habiting 49 91 51 95
Separated/divorced/widowed 26 49 27 50
Occupation
Farming/fishing 40·4 76 43·3 81
Business/employed 34·1 64 35·8 67
Housewife 12·2 23 12·3 23
Unemployed 13·3 25 8·6 16
Smoking
Never 73 138 74 139
Past 12 23 9 17
Current 15 28 17 32
Alcohol drinking 41 77 46 87
CD4 count (cells/ml) groups
, 50 3·7 7 3·7 7
50–199 37·2 70 36·2 68
200–349 27·2 51 30·8 58
$ 350 31·9 60 29·3 55
ART prior randomisation 16 30 11 21
CD4, cluster of differentiation 4; ART, antiretroviral therapy.
Table 2. Antiretroviral use among 376 pulmonary tuberculosis patients
at baseline and during a 5-month follow-up period
(Number of patients and percentages)
CD4 counts
(cells/ml)
Total
(n)
At baseline
At
2 months
At
5 months
n % n % n %
,350 261 38 14·6 74 28·4 103 39·5
$350 115 13 11·3 15 13·0 21 18·3
CD4, cluster of differentiation 4.
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in that patients receiving both Zn and other micronutrients
had an additional weight gain of 2·4 kg, and among those
who were HIV-co-infected, there was a 70 % reduction in
mortality. Based on these results, we wanted to test whether
supplementation with energy–protein in addition to micronu-
trients further improves weight and handgrip strength among
PTB þ HIV-co-infected patients, and how it affected arm
muscle or fat area.
In the present trial, we found no overall effects of the exper-
imental intervention on weight and body composition, but an
additional 1·3 kg increase in handgrip strength at 5 months,
although this was only marginally significant. This finding is
similar to that in the study in Singapore(24). In the Singaporean
study, investigators tested the effect of high-energy (including
protein) supplementation v. dietary advice on weight and grip
strength among TB patients for 6 weeks. They found that at
6 weeks, the intervention led to a considerable increase in
grip strength. However, in contrast to our findings, the
increase was associated with an increase in lean mass and
was not sustained at 6 months. These discrepancies between
the two studies may probably be explained by differences in
study populations and designs. For example, the Singaporean
study did not include HIV þ patients, whereas all the present
study participants were HIV-infected. Handgrip strength is a
proxy measure of work capacity and therefore its increase
among TB patients is important, because it may lead to
improved ability to produce or procure foods, and hence
patients may be able to better care their families.
Regarding the lack of overall effects, we see five possible
explanations. First, compliance with respect to the supplement
may have been inadequate, in that patients in the experimen-
tal arm may have not taken all the five additional biscuits or
the biscuits may have replaced rather than supplemented
the usual diet with 50 % of the requirements for a healthy
individual. Although our data suggest that compliance was
very high; this explanation cannot be ruled out considering
that most of the patients took the supplements at home and
thus their compliance was reported rather than observed.
Second, the present trial was not blinded, and thus data collec-
tors knew which patients were receiving the experimental
intervention, which may have resulted in information bias.
However, this is unlikely since such a bias would more prob-
ably have caused beneficial effects, rather than eliminated a
true effect. Third, the amount of protein and micronutrients
Table 3. Effect of energy–protein supplementation on weight, arm fat area, arm muscle area
and handgrip strength among 377 pulmonary tuberculosis patients at 2 and 5 months
(Number of patients, mean values and 95 % confidence intervals)
Energy–protein group (n 189) Control group (n 188)
n Mean 95 % CI n Mean 95 % CI P*
Weight (kg)
Baseline 189 50·9 49·6, 52·1 188 50·9 49·7, 52·2
2 months 166 54·0 52·5, 55·6 166 53·7 52·2, 55·1
Change† 166 2·9 2·3, 3·5 166 2·5 1·8, 3·1
Difference‡ 0·4 20·5, 1·4 0·33
5 months 151 57·3 55·8, 58·8 155 57·8 56·2, 59·4
Change† 151 6·0 5·2, 6·7 155 6·2 5·2, 7·1
Difference‡ 20·2 21·4, 1·0 0·75
Arm fat area (cm2)
Baseline 188 8·0 7·3, 8·7 186 7·8 7·0, 8·5
2 months 165 9·2 8·4, 9·9 168 9·2 8·3, 10·2
Change† 164 1·0 0·4, 1·5 167 1·3 0·9, 1·7
Difference‡ 20·3 21·0, 0·3 0·32
5 months 151 11·3 10·5, 12·2 155 11·2 10·1, 12·3
Change† 150 3·1 2·3, 3·8 153 3·3 2·6, 4·0
Difference‡ 20·2 21·2, 0·8 0·66
Arm muscle area (cm2)
Baseline 188 33·8 32·5, 35·0 186 32·8 31·5, 34·0
2 months 165 36·8 35·2, 38·4 168 35·1 33·7, 36·5
Change† 164 2·6 1·8, 3·5 166 2·1 1·3, 3·0
Difference‡ 0·50 20·7, 1·7 0·41
5 months 151 40·4 38·8, 41·9 155 39·9 38·3, 41·4
Change† 150 5·9 4·9, 7·0 153 6·3 5·2, 7·4
Difference‡ 20·4 21·9, 1·2 0·63
Handgrip strength (kg)
Baseline 188 24·1 22·9, 25·3 187 24·0 22·8, 25·2
2 months 166 26·6 25·2, 27·9 168 26·5 25·1, 27·9
Change† 165 2·3 1·6, 3·1 167 1·8 1·1, 2·6
Difference‡ 0·5 20·6, 1·5 0·37
5 months 151 30·4 29·1, 31·8 154 29·7 28·2, 31·1
Change† 150 6·0 5·0, 7·0 153 4·7 3·6, 5·7
Difference‡ 1·3 20·1, 2·8 0·07
* Difference assessed using the unpaired t test.
† Difference computed as the mean increase from baseline to follow-up.
‡ Difference computed as the mean change in the energy–protein group minus control group.
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Table 4. Effect of energy–protein supplementation on weight, arm fat area, arm muscle area and handgrip strength among 376 pulmonary tuberculosis patients at 2 and 5 months by cluster of
differentiation 4 (CD4) count groups
(Number of patients, mean values and 95 % confidence intervals)
Low CD4 count (,350 cells/ml) (n 261) High CD4 count ($350 cells/ml) (n 115)
Energy–protein group Control group Energy–protein group Control group
n Mean 95 % CI n Mean 95 % CI P * n Mean 95 % CI n Mean 95 % CI P * P†
Weight (kg)
Baseline 128 50·2 48·7, 51·8 138 50·2 48·7, 51·7 60 52·2 49·9, 54·5 55 52·8 50·7, 54·8
2 months 111 53·0 51·2, 54·8 119 53·0 51·1, 54·8 55 56·2 53·4, 59·0 47 55·4 55·3, 57·4
Change‡ 111 2·4 1·7, 3·1 119 2·6 1·8, 3·4 55 4·0 2·7, 5·3 47 2·1 0·9, 3·3
Difference§ 20·2 21·3, 0·8 0·66 1·9 0·1, 3·7 0·04 0·03
5 months 105 56·8 55·0, 58·5 111 57·2 55·1, 59·2 46 58·6 55·9, 61·4 44 59·3 57·1, 61·6
Change‡ 105 6·0 5·0, 6·9 111 6·3 5·2, 7·4 46 6·0 4·6, 7·3 44 5·9 4·2, 7·5
Difference§ 20·3 21·8, 1·1 0·67 0·1 22·0, 2·2 0·92 0·75
Arm fat area (cm2)
Baseline 127 8·0 7·1, 8·9 131 7·4 6·6, 8·3 60 8·0 6·9, 9·1 55 8·5 6·9, 10·1
2 months 110 9·2 8·2, 10·1 120 9·0 7·9, 10·1 55 9·2 8·0, 10·4 48 9·7 7·8, 11·7
Change‡ 109 0·8 0·2, 1·5 118 1·4 0·9, 1·9 55 1·3 0·4, 2·2 48 1·1 0·3, 1·9
Difference§ 20·6 21·4, 0·2 0·16 0·2 21·0, 1·4 0·76 0·30
5 months 105 11·4 10·4, 12·4 111 11·0 9·7, 12·2 46 11·1 9·5, 12·7 44 11·7 9·4, 13·9
Change‡ 104 3·0 2·1, 3·9 109 3·4 2·6, 4·3 46 3·1 1·7, 4·5 44 2·8 1·5, 4·1
Difference§ 20·4 21·6, 0·8 0·49 0·3 21·6, 2·2 0·78 0·54
Arm muscle area (cm2)
Baseline 127 33·2 31·6, 34·7 131 32·2 30·7, 33·6 60 34·9 32·6, 37·2 55 34·2 31·7, 36·6
2 months 110 36·3 34·3, 38·2 120 33·9 32·3, 35·6 55 37·9 35·1, 40·8 48 37·9 35·3, 40·5
Change‡ 109 2·5 1·4, 3·7 118 1·9 0·9, 2·9 55 2·9 1·7, 4·1 48 2·6 0·8, 4·5
Difference§ 0·6 20·9, 2·1 0·44 0·3 21·9, 2·4 0·82 0·79
5 months 105 39·9 38·0, 41·8 111 38·9 37·0, 40·7 46 41·4 38·5, 44·4 44 42·4 39·5, 45·3
Change ‡ 104 5·9 4·6, 7·2 109 6·0 4·6, 7·3 46 6·1 4·1, 8·0 44 7·3 5·2, 9·3
Difference§ 20·1 21·9, 1·8 0·97 21·2 24·0, 1·6 0·39 0·49
Handgrip strength (kg)
Baseline 127 23·1 21·6, 24·5 133 23·5 22·2, 24·9 60 26·2 24·1, 28·3 54 25·2 22·7, 27·7
2 months 111 26·1 24·5, 27·7 120 25·8 24·2, 27·5 55 27·5 25·2, 29·9 48 28·1 25·3, 30·8
Change‡ 110 2·6 1·7, 3·6 120 1·9 1·0, 2·8 55 1·7 0·5, 2·8 47 1·7 0·3, 3·1
Difference§ 0·7 20·5, 2·0 0·26 20·005 21·8, 1·8 0·99 0·52
5 months 105 30 28·4, 31·7 110 28·6 26·9, 30·3 46 31·4 28·7, 34·0 44 32·4 29·6, 35·1
Change‡ 104 6·6 5·3, 7·8 110 4·3 3·0, 5·5 46 4·8 3·1, 6·4 43 5·8 3·8, 7·7
Difference§ 2·3 0·6, 4·1 0·009 21·0 23·5, 1·5 0·43 0·04
* Difference assessed using the unpaired t test.
† Test for interaction between energy–protein supplementation and CD4 count groups.
‡ Difference computed as the mean increase from baseline to follow-up.
§ Difference computed as the mean change in energy–protein minus the control group.
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provided per day or the duration of supplementation may
have been inadequate to support the accrual of new tissues.
Since both TB and HIV infections are catabolic pro-
cesses(11,25,26), the repletion of lean mass may require higher
amounts of protein and other nutrients to compensate for
the impairment in anabolism which is associated with infec-
tion(27–29). Furthermore, the amount of Zn and other type II
nutrients such as P and K provided may have been inadequate
to meet the demands for additional lean tissue synthesis posed
by additional intake of energy–protein. This is plausible
considering that Zn is essential in cell division and protein
synthesis(30) and both P and K are important in anabolism(31).
Fourth, the supplement may have increased physical activity
and hence energy requirements, rather than leading to
increased weight gain. Although this is likely, as reflected in
the marginally significant increase in handgrip strength, we
cannot ascertain it since we did not have the means to
assess energy balance. Fifth, inadequate disease treatment
may have led to low supplement intake and/or increased
energy expenditure. With respect to TB treatment, this is
unlikely to explain the lack of effect since as reported,
under the NTLP, the cure rate is high, prevalence of multi-
drug resistance TB is low and the proportion of patients
who might have atypical mycobacterial infection, i.e.
those with CD4 counts ,50 cells/ml(32), was about 3 %. How-
ever, with regard to HIV treatment, the proportion of patients
who were on ART was lower than expected at baseline and
throughout the follow-up period. For example, at baseline,
about 40 % of all patients had CD4 counts of ,200 cells/ml
and expected to be on ART, but only 13 % were receiving
antiretroviral drugs. Thus, it is likely that inadequate HIV
management may have contributed to the lack of effect of
the intervention probably due to recurrent opportunistic
infections.
Among the subgroups defined by CD4 count level, we
found the seemingly beneficial effect on weight at 2 months
among patients with higher CD4 counts and on handgrip
strength among those with lower CD4 counts at 5 months.
The differences in intervention effects at 2 months may prob-
ably be explained by a tendency to have a better nutrient
intake and metabolism among those with higher CD4 counts
compared with the general HIV-infected PTB þ population
and vice versa among those with lower CD4 counts. Similarly,
among the subgroups defined by ART use, we found that the
intervention tended to have a beneficial effect on handgrip
strength among patients who were on ART at 5 months.
This may suggest that among PTB þ HIV-infected patients,
irrespective of CD4 counts, ART may enhance the increase
in mass muscle and/or muscle function, which are the major
determinants of handgrip strength, probably because ART
may prevent against recurrent opportunistic infections, the
main cause of weight and possibly functional loss among
HIV-infected patients(33). In fact, the beneficial effect of the
intervention on handgrip strength at 5 months among patients
who had CD4 counts ,350 cells/ml at baseline may be
explained by the fact that at this time, 40 % of these patients
were receiving ART compared with only 18 % among those
with CD4 count $350 cells/ml.
At the end of 5 months, patients in both arms had gained
considerable weight, although this was only about 60 % of
7–10 kg of the deficits found at the beginning of TB treat-
ment(22,34). Although deficit in weight at the beginning of
treatment is due to many factors including pre-TB under-
weight and HIV infection, most of the deficit is due to active
TB(22). Therefore, nutritional support against a background
of TB treatment should ensure regaining of nearly all the def-
icit by the time treatment is completed. The suboptimal weight
recovery, even among the sub-group in which the experimen-
tal intervention seemed to be beneficial, may imply that
the nutritional support offered may have been inadequate in
composition, duration or timing.
The strength of the present trial is that it was randomised,
and that the overall loss to follow-up was modest. Although
the planned sample size was not achieved due to slow
recruitment pace, the study was large enough to detect clini-
cally important differences with high power. In addition, our
outcome measures included a functional outcome, i.e. hand-
grip strength, which is an important marker of health status
including survival(35). However, we only used proxies in
assessing body composition and did not have markers of
energy intake or expenditure and in most of our patients,
compliance was assessed using reported information.
Future studies should use better methods and include
mechanistic sub-studies in order to be able to fully explain
the findings.
Conclusions
Among PTB þ HIV-co-infected patients, energy–protein
supplementation against a background of high multi-
micronutrient intake had no overall effect on weight and
body composition, but had a marginally significant effect on
handgrip strength at 5 months. More studies are needed
to develop a macronutrient supplement for TB patients co-
infected with HIV, with effects on lean mass, functional
outcomes and survival, before it can be recommended to TB
programmes.
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